A B S T R A C T The current concepts ofthe pathogenesis of emphysema hold that progressive, chronic destruction ofthe alveolar structures occurs because there is an imbalance betwveen the proteases and antiproteases in the lower respiratory tract. In this context, proteases, particularly neutrophil elastase, work unimpeded to destroy the alveolar structures. This concept has evolved from consideration of patients with alantitrypsin deficienciy, who have decreased levels of serum al-antitrypsin and who have progressive panaciiar emphysema. To directly assess the antiprotease side of this equation, the lower respiratory tract of nonsmoking individuals with normal serum antiproteases and individuals with PiZ homozygous al-antitrypsin deficiency underwent bronchoalveolar lavage to evaluate the antiprotease screen of their lower respiratory tract. These studies demonstrated that: (a) al-antitrypsin is the major antielastase of the normal human lower respiratory tract; (b) a2-macroglobulin, a large serum antielastase, and the bronchial mucous inhibitor, an antielastase of the central airways, do not contribute to the antielastase protection of the human alveolar structures; (c) individuals with PiZ al-antitrypsin deficiency have little or no al-antitrypsin in their lower respiratory tract and have no alternative antiprotease protection against neutrophil elastase; and (d) the lack of antiprotease protection of the lower respiratory tract of PiZ individuals is a chronic process, suggesting their vulnerability to neutrophil elastase is always present.
INTRODUCTION
Emphysema is a chronic disorder of the alveolar structuires associated with enlargement ofthe distal air spaces, accompanied by destruction of their walls (1) . The first major clue to the pathogenesis of alveolar wall destruction in emphysema came from the observation that individuals deficient in serum al-antitrypsin had severe early-onset emphysema (2, 3) . Because al-antitrypsin is the major serum antielastase (4) , this observation led to what is known as the protease-antiprotease theory of emphysema (5) (6) (7) (8) . This theory holds that the alveolar structures are under constant attack by proteases, particularly elastase, released by inflammatory cells, but are protected from destruction by an antiprotease screen that effectively inhibits this elastase. Because severe deficiency in serum al-antitrypsin is associated with early-onset, progressive emphysema, the protease-antiprotease theory also predicts: (a) alantitrypsin must be the major antielastase of the alveolar structures; (b) patients with a deficiency of serum alantitrypsin would have little or no antielastase activity in their lower respiratory tract; and (c) the lack of antielastase screen in the lungs of al-antitrypsin-deficient individuals is a chronic process.
The present study was designed to evaluate these predictions. To do so, we used the technique ofbronchoalveolar lavage to sample the epithelial lining fluid of the lower respiratory tract of a group of nonsmoking, homozygous PiZ individuals with severe emphysema. These findings were compared with the antielastase screen in the lower respiratory tract of two groups: nonsmoking, homozygous PiM individuals with normal lung function; and non-smoking, homozygous PiM individuals with idiopathic pulmonary fibrosis, a chronic inflammatory disorder of the lower respiratory tract associated with interstitial fibrosis, not emphysema (9) .
METHODS
Study Population Nornmal subjects. Eight healthy, nonsmoking volunteer bronchoalveolar lavage. There were five males and three females with a mean age of 32+5 yr.' All individuals had normal chest roentgenograms and all had normal vital capacity, total lung capacity, diffusing capacity, forced expiratory volume in 1 s (FEV,),2 FEVJ/forced vital capacity, and mid-maximum expiratory flow rate.
Patients with al-antitrypsin deficiency. Eight patients (seven males, one female, mean age 42±5 yr) with severe serum deficiency of al-antitrypsin and advanced emphysema were admitted to the NIH Clinical Center. One never smoked and seven had not smoked for at least 2 yr. Chest films of all eight showed hyperinflation, flattened diaphragms, a small heart, loss of vascular markings, and bilateral basilar bullous disease. As a group, these individuals had a mild decrease in vital capacity (82±10% predicted), normal total lung capacity (97±8% predicted by helium dilution), marked airway obstruction (FEVy, 1.1±0.2 liters; FEV,, 54±10% predicted, FEV,/FVC, 42±5% predicted; mid-maximum expiratory flow rate 15±5% predicted), hyperinflation (residual volume/total lung capacity, 0.52±0.10), and reduced diffusing capacity (42±10% predicted, single breath based on volume and hemoglobin). No individuals in this group had a history of sputum production in the past year.
Idiopathic pulmonaryfibrosis. Seven patients (five males, two females, mean age 45±5 yr) with biopsy-proven idiopathic pulmonary fibrosis (IPF) in mid-course were admitted to the NIH Clinical Center. None ofthese individuals was a cigarette smoker. All had chest films showing small lungs and a diffuse reticulonodular infiltrate. As a group, these individuals had reduced lung volumes (vital capacity, 66±7% predicted; total lung capacity, 61±5% predicted; normal FEV,%, (98±2% predicted); and reduced diffusing capacity (56±10% predicted). No individual in the group had a history ofsputum production.
Serum al-antitrypsin phenotyping and al-antitrypsin levels Sera ofall patients were analyzed by isoelectric focusing (10) in precast, ampholine-containing polyacrylamide slab gels (pH 4-6; LKB Instruments, Inc., Rockville, Md.). The nine normal subjects all had the PiM phenotype, the seven patients with severe serum al-antitrypsin deficiency all had the PiZ phenotype, and the seven patients with IPF all had the PiM phenotype.
Serum levels of al-antitrypsin in all subjects were determined using radial immunodiffusion plates obtained from Calbiochem-Behring Corp., American Hoechst Corp., (San Diego, Calif.) (11) . The al-antitrypsin levels were confirmed by "rocket" electroimmunodiffusion using monospecific goat antiserum to human al-antitrypsin (Atlantic Antibodies, Westbrook, Maine) (12) .
Bronchoalveolar lavage
All patients subject to lavage had an FEV, of -0.75 liters. Five, 20-ml aliquots of sterile 0.9% saline were used to lavage the right middle lobe or the lingula segment of the left upper lobe; potential contamination of the sample by central airway secretions was prevented by advancing the bronchoscope into the "wedge" position. The distal tip of the Olympus ' All statistical data are presented as mean ±standard error of the mean; all comparisons are made using the two-tailed Student's t test. 2Abbreviations used in this paper: ELISA, enzyme-linked immunoassay; FEV,, forced expiratory volume in 1 s; IPF, idiopathic pulmonary fibrosis. fiberoptic bronchoscope (model BF/B3, Olympus Corporation of America, New Hyde Park, N. Y.) used in this study has a diameter of 5 mm. When extended to a wedge position, this instrument permits the isolation and lavage of the lower respiratory tract at the level of airways whose caliber is 4 mm and less. The lavage fluid was recovered in a sterile vacuum trap, and the cellular and fluid phases immediately separated by centrifugation at 500 g for 5 min. The fluid phase was then concentrated by nitrogen pressure dialysis (Amicon UM2 membrane, Amicon Corp., Scientific Systems Div., Lexington, Mass.) to a final volume of 1.0 ml, buffered with 1.0 M Tris-HCI, pH 7.4 (5% by volume), and stored in liquid nitrogen vapor until analyzed (13) .
Immunochemical evaluation of antielastases in lavage fluid al-Antitrypsin and a2-macroglobulin levels in bronchoalveolar lavage fluid were determined with radial immunodiffusion (Calbiochem-Behring), and rocket electroimmunodiffusion using monospecific goat antiserum to al-antitrypsin and a2-macroglobulin, respectively (Atlantic Antibodies). As previously described, the levels of al-antitrypsin and a2-macroglobulin in lavage fluid were compared to lavage fluid albumin levels determined by radial immunodiffusion. Serum al-antitrypsin, a2-macroglobulin, and albumin levels were simultaneously determined to provide comparison data for the lavage antielastase/albumin levels.
The state of the al-antitrypsin in concentrated lavage fluid of normal subjects was evaluated using two-dimensional immunoelectrophoresis in agarose at pH 8.1 (14) . Purified, normal al-antitrypsin and al-antitrypsin complexed with human neutrophil elastase were used as standards.
Enzyme-linked immunoassay (ELISA) for human a2-macroglobulin was performed as described (15) . Briefly, wells of polystyrene microelisa plates (Dynatech Laboratories, Inc., Alexandria, Va.) were coated with 1.6 ,ug of purified human a2-macroglobulin (16) in Voller's buffer (17) . Monospecific goat anti-human a2-macroglobulin (Miles Laboratories, Inc., Miles Research Products, Elkhart, Ind.) diluted 1:2,000 was mixed with an equal volume of sample or standard and 0.2 ml of the mixture was transferred to the rinsed coated plate. a2-Macroglobulin in the sample blocked binding of the antibody to the antigen-coated plastic well. The amount of antibody that did bind was quantitated by adding a second antibody, 1:1,500 dilution of horseradish peroxidase-conjugated rabbit anti-goat immunoglobulin (IgG) followed by a colorless substrate (o-phenylenediamine, Aldrich Chemical Co., Inc., Milwaukee, Wis.) for the peroxidase which is converted into a chromophore and measured spectrophotometrically (15) . The test was sensitive to 25 ng/ml and was able to reliably detect a2-macroglobulin in complex biological fluids such as plasma or bronchoalveolar lavage fluid (16) .
Counterimmunoelectrophoresis (18) in agarose was used to detect the bronchial mucous inhibitor in lavage samples. Using a monospecific antibody (kindly provided by Dr. Harvey Carp; State University of New York at Stony Brook), this immunoassay was able to detect the inhibitor when present at concentrations as low as 2 ug/ml. Central airway secretions obtained from saline lavage of human subjects via endotracheal tubes were used as a positive control for the immunochemical detection ofthe bronchial mucous inhibitor.
Functional activity of lung antiproteases
To evaluate the functional activity ofthe antiproteases ofthe lower respiratory tract of the three study groups, concentrated 890 Gadek, Fells, Zimmerman, Rennard, and Crystal bronchoalveolar lavage fluid was tested for inhibitory activity against purified human neutrophil elastase. The neutrophil enzyme was used throughout this study, because it represents the elastase which bears physiologic relevance to the emphysematous process (19, 20) and because, unlike porcine pancreatic elastase, it is inhibited by the bronchial mucous inhibitor (21) whose role in the lower respiratory tract we sought to clarify. Human neutrophil elastase was purified by the procedure of Taylor and Crawford (22); sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the purified product showed a single protein band with a molecular weight of -30,000. The 1.0 ,ug ofpurified enzyme degraded 200 ,ug ofinsoluble elastin in 24 h. The insoluble [3H]elastin substrate used in these studies was prepared as described by Takahashi (23) ; the substrate had a specific activity of 500 dpm/,ug.
To test lavage fluid antielastase activity, the concentrated lavage fluid was incubated with 1.0 ,ug purified neutrophil elastase at 23°C for 45 min. For all assays, the volume of lavage fluid added was that which contained 50 Ag ofalbumin.
This mixture was then added to 200 ,ug of the [3H]elastin substrate in the presence of 100 mM Tris-HCl, pH 7.4 (final volume 300 jul) and incubated at 370C for 18 h. For each group of patients evaluated, lavage fluid from at least 3 PiM normal controls were assayed in parallel. The data for the controls were averaged, and that value was considered to represent 100% functional antielastase activity. The functional antielastase activity of the patient groups was then expressed as the percentage of elastase inhibition afforded by the lavage fluid of the average normal controls. Correction for differences in dilution of the lavage fluid samples was made on the basis of albumin concentration in the sample (13) .
To determine the importance of al-antitrypsin as an antielastase in the lower respiratory tract, al-antitrypsin was removed from concentrated bronchoalveolar lavage fluid of normal individuals using immunoprecipitation with anti-al-antitrypsin. To accomplish this, the IgG fraction of monospecific goat antihuman al-antitrypsin was added to the lavage sample in a quantity which removed all antigenic al-antitrypsin from the sample; the efficacy of the process was confirmed by radial immunodiffusion. The lavage fluid was then evaluated for residual antielastase activity using the assay described above.
To insure that the al-antitrypsin in the lavage fluid of the PiM normal controls had not lost antielastase activity during processing, the amount of al-antitrypsin in lavage fluid was determined by rocket immunoelectrophoresis and expressed as moles of al-antitrypsin/moles of lavage fluid albumin. This sample was then tested in the functional antielastase assay described above and the micromoles of lavage fluid al-antitrypsin required to inhibit 1 ,Lmol purified neutrophil elastase was determined (24) .
Analysis of the influence of alveolar macrophages on the recovery of antielastases from the human lower respiratory tract Normal human alveolar macrophages were obtained by bronchoalveolar lavage (13) and cultured in sterile plastic plates (Costar; Cambridge, Mass.) at a concentration of 106/ml in Gey's solution (Microbiological Associates, Walkersville, Md.). The buffer was diluted with sterile 0.15 M NaCl to obtain an albumin content approximating that of lavage fluid (1 mg/ml). Purified human al-antitrypsin and a2-macroglobulin (16) were added to the macrophage cultures to provide a final concentration of these antielastases of 200 ,ug/ml. Purified human neutrophil elastase was then added to the macrophage cultures (supplemented with al-antitrypsin and a2-macroglobulin) in amounts ranging from 1 to 100 gg/ml (final concentration in culture). The alveolar macrophage cultures, containing varying amounts of neutrophil elastase and constant amounts of al-antitrypsin and a2-macroglobulin, were then incubated at 370C with constant mixing for 60 min. After this incubation the suspensions were centrifuged (1,500 g for 10 min) and the supernates were analyzed for the content of al-antitrypsin (rocket immunoelectrophoresis), a2-macroglobulin (ELISA), the uninhibited neutrophil elastase activity ([3H]elastin substrate), and the formation of neutrophil elastase-antielastase complexes (immunoelectrophoresis).
Molecular sieve chromatography
To determine the molecular weight of the antielastases in the lavage fluid of normal individuals, concentrated bronchoalveolar lavage fluid (0.5 ml) was chromatographed on a 40-x 2.5-cm column of G-75 Sephadex (Pharmacia Fine Chemicals, Div. of Pharmacia Inc., Piscataway, N. J.) in 0.5 M NaCl-0.03 M Tris-HCl, pH 7.4 (40C). 0.5-ml fractions were collected and assayed directly for functional activity against human neutrophil elastase as well as antigenic activity for a2-macroglobulin and al-antitrypsin. The column was calibrated with dextran blue (mol wt, 1,000,000), ovalbumin (45,000), and cytochrome c (12,500).
Sequential evaluation of PiZ lung antielastase screen
To establish the chronicity of the lack of antielastase protection of the lower respiratory tract of PiZ individuals, three patients with PiZ al-antitrypsin deficiency were lavaged several times over a 6-to 12-mo period. The lavage fluid was handled as described above and the antielastase activity determined. Three PiM individuals with idiopathic pulmonary fibrosis were evaluated in a similar fashion for comparison. The antielastase activity in the lavage fluid was expressed as a percentage of antielastase activity of lavage fluid of a group of PiM normal individuals as described above.
RESULTS
Immunochemical determinations ofantiproteases in serum and bronchoalveolar lavage in normal subjects.
The mean serum level of al-antitrypsin in the nine normal subjects was 187+32 mg/dl (Fig. 1) . The bronchoalveolar lavage al-antitrypsin in these individuals was 51+10 ,ug/mg albumin. This value for lavage fluid al-antitrypsin per milligrams of albumin was in close agreement with the serum al-antitrypsin expressed as a function of serum albumin in these subjects (serum al-antitrypsin 53±11 ,ug/mg albumin, P > 0.3), suggesting that the al-antitrypsin present in the normal lower respiratory tract is not produced or concentrated within the lung but rather represents a filtrate of plasma. The serum a2-macroglobulin in these normal subjects was 254+45 mg/dl (Fig. 1) . In contrast, a2-macroglobulin was below detectable limits in the concentrated bronchoalveolar lavage fluid obtained from normals. Since the minimal detectable levels of a2-macroglobulin in the rocket electroimmunodiffusion assay was 3 Ag, this
Antielastases of the Human Alveolar Structures In order to verify the low values of a2-macroglobulin in the human lower respiratory tract suggested by the electroimmunodiffusion assay, an ELISA was adapted for the detection of a2-macroglobulin in bronchoalveolar lavage (15) . Using both purified human a2-macroglobulin and normal human serum as standards, the mean a2-macroglobulin content ofbronchoalveolar lavage was 2.1±0.2 ,ug/mg albumin in four normal subjects, and 2.4±0.1 ,ug/mg albumin in five PiZ individuals (P > 0.2). These values confirm that, although detectable in lavage samples, a2-macroglobulin represents <0.5% of the molar content of lower respiratory tract antielastases when compared to the other major serum antielastase, al-antitrypsin.
Functional antielastase activity in the normal human lower respiratory tract. Lavage fluid obtained from the lower respiratory tract of normal PiM subjects was an effective inhibitor of human neutrophil elastase activity against an insoluble elastin substrate. In the assay used, 1 ,ug elastase released 100,000 dpm from 200 ,ug of elastin substrate in 24 h. When lavage fluid (equivalent to 50 ,ug lavage fluid albumin) from a typical PiM normal subject was added, <5,000 dpm elastin was released by 1 ,ug of neutrophil elastase.
To verify that al-antitrypsin represents the principal form of functional antielastase activity within the normal lower respiratory tract, monospecific, IgG antibody to al-antitrypsin was used to deplete the normal PiM lavage fluid of its al-antitrypsin. After addition of this antibody, the lavage fluid was again adjusted to an albumin content of 50 ug/ml, and its elastase inhibitory activity measured (Fig. 2) . Addition of this antibody to the PiM normal lavage fluid removed nearly all the functional antielastase activity present. Neither addition of buffer nor antibody to albumin affected the antielastase activity of the fluid (data not shown). If antielastases other than al-antitrypsin (e.g., a2-macroglobulin, bronchial mucous inhibitor) were present in the lower respiratory tract of normal individuals, removal of al-antitrypsin would have left antielastase activity in the lavage fluid. We can conclude, therefore, that al-antitrypsin is the major antineutrophil elastase of the normal human lower respiratory tract.
Further evidence that al-antitrypsin is the principal source of functional antielastase protection of the normal human lower respiratory tract was provided by (Fig. 4D) . Thus, standard (data not immunochemical studies suggest that individuals with ypsin the only anti-serum al-antitrypsin deficiency have no detectable alratory tract, but the antitrypsin in their lower respiratory tract and that, icomplexed form. within their alveolar structures, there is no "coiimpensaeolar macrophage-tory" increase of a2-macroglobulin to provide an alprotease complexes ternative form of antielastase. (PiZ individuals possess acroglobulin in the a mean of 2.4±0.1 ,g of a2-macroglobulin per milli-,s a possible effect gram of albumin in their lavage fluid, see above.) of protease-antiproIf al-antitrypsin is the principal antielastase at the tion of antielastase level of the alveolar structures, then analysis of funcluid, a simulation of tional antielastase activity in the lower respiratory tract ed. Normal human of al-antitrypsin-deficient individuals would be pred in the presence of dicted to be negligible. In fact, this was the case (Fig. 5) . erum antielastases, The fluid recovered from the lower respiratory tract of lin (Table I) . After PiZ individuals demonstrated ninefold less antielastase s of neutrophil elas-activity than was recovered from the lungs of normiial 894 Gadek, Fells, Zimmerman, Rennard, and Crystal Chronicity oflack ofantielastase screen in the lower respiratory tract in PiZ individuals. al-Antitrypsin deficiency is a chronic disease in which there is slowly progressive destruction of the alveolar structures. The protease-antiprotease theory of emphysema would predict, therefore, that the lack of antielastase screen in the lower respiratory tract of the PiZ subject would be a chronic condition. To insure that this was the case, three PiZ individuals and three PiM patients with IPF were sequentially lavaged over a 6-to 12-mo period. As predicted by the protease-antiprotease theory, the PiZ individuals had little change in their diminished antielastase screen when they were evaluated at each time point. In contrast, the patients with IPF had adequate antielastase protection in their lower respiratory tract throughout the study period (Fig. 6 ).
DISCUSSION
Because al-antitrypsin is the major serum antielastase (4) and individuals deficient in serum al-antitrypsin have early-onset, progressive destruction oftheir lower respiratory tract, the protease-antiprotease theory of emphysema predicts that al-antitrypsin provides the major antielastase screen for the human alveolar structures. The present study confirms that prediction and demonstrates that individuals with al-antitrypsin have no alternative antielastase in their lower respiratory tract.
al-Antitrypsin is the major antielastase of the human lower respiratory tract. The current concepts of the pathogenesis of emphysema suggest that alveolar destruction is mediated, at least in part, by the unimpeded action of neutrophil elastase (5) (6) (7) (8) 26) (27) . The fact that this elastase is not inhibited by al-antitrypsin (27) and that experimental models do not exist make it difficult to integrate macrophage elastase into the protease-antiprotease theory. This theory draws heavily from the clinical model of serum al-antitrypsin deficiency and is challenged by the discovery of an alternative, locally produced, respiratory tract antielastase, the bronchial mucus inhibitor (21) . Thus, validation of this concept requires demonstration that the major functional antielastase within the lower respiratory tract is al-antitrypsin. Several pieces ofevidence support this concept: (a) Immunochemical quantitation of the major serum antielastases (al-antitrypsin and a2-macroglobulin) in bronchoalveolar lavage fluid of normal individuals demonstrated that while lung al-antitrypsin concentration (relative to albumin) is similar to serum, lung a2-macroglobulin concentration is 25 times less than its serum concentration. Since al-antitrypsin and a2-macroglobulin inhibit neutrophil elastase in equimolar amounts, the observation suggests that al-antitrypsin contributes at least 200-fold more antielastase protection to the lower respiratory tract than could a2-macroglobulin. This is not to suggest that a2-macroglobulin is not important to the human lung, but rather that its presence in the alveolar structures, at a level some 25 times lower than the serum level, is not sufficient to maintain elastase-antielastase homeostasis in the alveolar structures. In this context, perhaps the primary role of a2-macroglobulin in the human lower respiratory tract concerns the modulation of proteases for which al-antitrypsin cannot serve as an effective antiprotease (e.g., neutrophil collagenase or the proteases of the coagulation and fibrinolytic pathways) (28) .
(b) Removal of al-antitrypsin from lavage fluid of normal individuals results in virtually complete loss of the functional antielastase activity recovered from the lower respiratory tract.
(c) Molecular sieve chromatography of bronchoalveolar lavage fluid of normal individuals demonstrated that the only functional antielastase activity retrievable from the normal human lower respiratory tract coeluted with al-antitrypsin.
(d) Analysis of the influence of alveolar macrophages on the local clearance of a2-macroglobulin suggests that, in the presence of al-antitrypsin, receptor-mediated clearance does not alter local a2-macroglobulin concentration.
Clearly, therefore, al-antitrypsin is the primary antielastase of the lower respiratory tract of normal man. Since al-antitrypsin has a molecular weight of 52,000 (6) , it diffuses through the alveolar structures from the endothelial to the epithelial surface with relative ease. In this context, metabolic studies of radioiodinated al-antitrypsin show that the labeled protein is recovered in bronchoalveolar lavage fluid in quantities comparable to the activity in plasma when normalized to the albumin content of the fluid.3 In contrast, a2-macroglobulin is of large (725,000 daltons) molecular weight, a molecular size that appears readily excluded from diffusion by alveolar-capillary structures. While a2-macroglobulin may be produced locally by alveolar macrophages (27) , the present study suggests that the level of production in vivo must be quite low.
Even though another antielastase (the so-called "bronchial mucous inhibitor") has been found in human lung (21, (29) (30) (31) (32) , the present study suggests that the bronchial mucous inhibitor must be confined to more central airways rather than in those regions of lung sampled by the fiberoptic bronchoscope. This data is consistent with the findings of Tegner (31) , who has shown that the bronchial mucous inhibitor accounts for -80% of the neutrophil elastase-inhibitory activity in epithelial fluid recovered from the large airways. Unlike plasma-derived al-antitrypsin, which diffuses through the alveolar structures, the bronchial mucous inhibitor is likely secreted by the epithelial cells and/or mucous acinar cells of the upper respiratory tract (33) . Since al-antitrypsin seems to contribute little to the antielastase screen of the central airways, we may conclude from Tegner's and the present study that alantitrypsin is the major antielastase ofthe lower respiratory tract while the bronchial mucous inhibitor affords antielastase protection of the upper respiratory tract. Three individuals with PiZ al-antitrypsin deficiency were lavaged two to three times each over a 6-to 12-mo period. (36) .
Implications for the therapy of al-antitrypsin deficiency. Although it is estimated that -20% of homozygous individuals with al-antitrypsin deficiency do not develop emphysema, the disease is fatal in the majority of deficient individuals (5, 7). Since cigarette smoking appears to greatly accelerate this destructive lung disease (37) , presumably by increasing the influx of elastase-containing neutrophils into alveolar structures (38) , cessation of cigarette use becomes the initial point of attack in this disease. Because al-antitrypsin deficiency is clearly associated with the deficiency in the antielastase screen in the lower respiratory tract, a rational approach to the therapy of this disease would be to increase the serum al-antitrypsin levels (hence the lung antielastase screen) (39) . In this regard, two therapeutic strategies for these patients are under study.
First, PiZ patients are being treated with danazol, an impeded androgen that increases serum levels of Cl esterase inhibitor, another liver-produced antiprotease (40, 41) . Preliminary studies in seven al-antitrypsindeficient individuals treated for 1 mo showed that danazol administration increased serum al-antitrypsin levels by an average of 40% (42) . While this is not the serum al-antitrypsin level thought to completely protect the lower respiratory tract, it does bring the al-antitrypsindeficient individual closer to the theoretical protective threshold. Presently, we are evaluating this treatment over a 1-yr period to determine if chronic administration of this drug can maintain increased al-antitrypsin levels in these patients. Second, a small group of PiZ patients with severe emphysema have been treated with direct intravenous infusion with partially purified al-antitrypsin (25) . Preliminary studies suggest that, with a once weekly administration, serum and lung al-antitrypsin levels can be maintained at or above the protective threshold level. Thus, it may be possible to directly replenish the antielastase protection of the alveolar structures of such individuals by intermittent, direct parenteral administration.
